Development asset linked to EUPRAXIA PHARMACEUTICALS in public FDA and regional records. Molecular target: Adrenocorticotropic hormone receptor.
- Target
- Adrenocorticotropic hormone receptor
- Mechanism
- Melanocortin receptor 2 agonist
pharma · Osteoarthritis, Knee · Eosinophilic esophagitis · EPRX
EUPRAXIA PHARMACEUTICALS
EUPRAXIA PHARMACEUTICALS INC.
EUPRAXIA PHARMACEUTICALS drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Victoria, CA HQ
2012 Founded
52 Employees
Public company Type
EPRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Victoria, CA
- Founded
- 2012
- Employees
- 52
- Programs
- 4
- Drugs
- 1
- Patents
- 3
EUPRAXIA PHARMACEUTICALS pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
EUPRAXIA PHARMACEUTICALS drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.